Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Recruiting · NCT06795009 · Registry updated 2025-12-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine cancer, uterine disorder | Recruiting | Phase 1 | 2025-12-11 | NCT06795009 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Exelixis | 77 |
| National Cancer Institute (NCI) | 3015 |
| Washington University School of Medicine | 475 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Francisco | San Francisco | United States | 294 |
| University of New Mexico | Albuquerque | United States | 17 |
| University of Oklahoma | Oklahoma City | United States | 28 |
| Washington University School of Medicine | St Louis | United States | 895 |